相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale
Daranjit Sandhu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Synthesis and Evaluation of Voltage-Gated Sodium Channel Blocking Pyrroline Derivatives Endowed with Both Antiarrhythmic and Antioxidant Activities
Alessia Carocci et al.
CHEMMEDCHEM (2021)
The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure
Nathalia Fonseca Nadur et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Therapeutic Potential of Regorafenib-A Multikinase Inhibitor in Pulmonary Hypertension
Swathi Veeroju et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility
Giulia Ferrannini et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
Dual-Functional MN-08 Attenuated Pulmonary Arterial Hypertension Through Vasodilation and Inhibition of Pulmonary Arterial Remodeling
Fangcheng Luo et al.
HYPERTENSION (2021)
Treatment of Heart Failure With Mid-Range Ejection Fraction: A Summary of Current Evidence
Teng Ma et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Simple heteroaryl modifications in the 4,5-diarylisoxazol-3-carboxylic acid scaffold favorably modulates the activity as dual mPGES-1/5-LO inhibitors with in vivo efficacy
Tugba Gurses et al.
BIOORGANIC CHEMISTRY (2021)
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Bei Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
A Review of the Proposed Mechanistic Actions of Sodium Glucose Cotransporter-2 Inhibitors in the Treatment of Heart Failure
Brandon Nightingale
CARDIOLOGY RESEARCH (2021)
Treatment of pulmonary hypertension with riociguat: a review of current evidence and future perspectives
Afroditi K. Boutou et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
LigBuilder V3: A Multi-Target de novo Drug Design Approach
Yaxia Yuan et al.
FRONTIERS IN CHEMISTRY (2020)
A review on mPGES-1 inhibitors: From preclinical studies to clinical applications
Filip Bergqvist et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2020)
A potent antiarrhythmic drug N-methyl berbamine extends the action potential through inhibiting both calcium and potassium currents
Huiyuan Hu et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2020)
New applications of squalene synthase inhibitors: Membrane cholesterol as a therapeutic target
Angeliki P. Kourounakis et al.
ARCHIV DER PHARMAZIE (2020)
5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors
Guozhang Xu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Discovery of Novel Pyrazolo[3,4-b] Pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension
Liqing Hu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Two for the Price of One: Heterobivalent Ligand Design Targeting Two Binding Sites on Voltage-Gated Sodium Channels Slows Ligand Dissociation and Enhances Potency
Alicia Peschel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
Stefan D. Anker et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives
Wei Zheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Review Current and emerging therapeutic approaches to pulmonary hypertension
Malik Bisserier et al.
REVIEWS IN CARDIOVASCULAR MEDICINE (2020)
New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension
Valentina Mercurio et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Heart failure drug treatment
Patrick Rossignol et al.
LANCET (2019)
Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology
Camilla Normand et al.
LANCET (2019)
Shooting three inflammatory targets with a single bullet: Novel multi-targeting anti-inflammatory glitazones
Perihan A. Elzahhar et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Pharmacokinetics-Driven Optimization of 4(3H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension
Zhen Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Identification of new dual FABP4/5 inhibitors based on a naphthalene-1-sulfonamide FABP4 inhibitor
Yulong He et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
ZYZ-803 Mitigates Endoplasmic Reticulum Stress-Related Necroptosis after Acute Myocardial Infarction through Downregulating the RIP3-CaMKII Signaling Pathway
Lingling Chang et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2019)
Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation
Takeo Tsutsumi et al.
PLOS ONE (2019)
Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study
Annika Rosengren et al.
LANCET GLOBAL HEALTH (2019)
Is the long-term decline in cardiovascular-disease mortality in high-income countries over? Evidence from national vital statistics
Alan D. Lopez et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2019)
Atherosclerosis
Peter Libby et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Conotoxins: Chemistry and Biology
Ai-Hua Jin et al.
CHEMICAL REVIEWS (2019)
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
Emanuele Di Angelantonio et al.
LANCET GLOBAL HEALTH (2019)
Structural Basis of Nav1.7 Inhibition by a Gating-Modifier Spider Toxin
Hui Xu et al.
CELL (2019)
Discovery of TD-0212, an Orally Active Dual Pharmacology AT(1) Antagonist and Neprilysin Inhibitor (ARNI)
R. Murray McKinnell et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Optimizing the Pharmacological Profile of New Bifunctional Antihyperlipidemic/Antioxidant Morpholine Derivatives
Alexios N. Matralis et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Prostanoid EP4 agonist L-902,688 activates PPARγ and attenuates pulmonary arterial hypertension
Hsin-Hsien Li et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2018)
Design, synthesis and cardiovascular evaluation of some aminoisopropanoloxy derivatives of xanthone
M. Kubacka et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
From hit to lead: Structure-based discovery of naphthalene-1 sulfonamide derivatives as potent and selective inhibitors of fatty acid binding protein 4
Ding-Ding Gao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Identification of a Novel Hybridization from Isosorbide 5-Mononitrate and Bardoxolone Methyl with Dual Activities of Pulmonary Vasodilation and Vascular Remodeling Inhibition on Pulmonary Arterial Hypertension Rats
Yusheng Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Evolving targets for the treatment of atherosclerosis
Ankita Solanki et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats
Jingwen Xia et al.
FRONTIERS IN PHARMACOLOGY (2018)
Scorpion Toxins Targeting Voltage-gated Sodium Channels Associated with Pain
Yijia Xu et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2018)
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017
Gregory A. Roth et al.
LANCET (2018)
Design, Synthesis, Experimental and Theoretical Characterization of a New Multitarget 2-Thienyl-N-Acylhydrazone Derivative
Isadora T. S. Bastos et al.
PHARMACEUTICALS (2018)
A perspective on multi-target drug discovery and design for complex diseases
Rona R. Ramsay et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
Discovery of 2-(((1r,4r)-4-(((4Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy) acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
Thuy-Anh Tran et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015
Gregory A. Roth et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Forty Years of Sodium Channels: Structure, Function, Pharmacology, and Epilepsy
William A. Catterall
NEUROCHEMICAL RESEARCH (2017)
Acute Myocardial Infarction
Jeffrey L. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
Tian-Yu Lian et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
Bin Li et al.
CURRENT PHARMACEUTICAL DESIGN (2017)
Oxidative Stress in Atherosclerosis
Ajoe John Kattoor et al.
CURRENT ATHEROSCLEROSIS REPORTS (2017)
Ivabradine: A Review of Labeled and Off-Label Uses
Carrie S. Oliphant et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2016)
The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling
Elizabeth A. Vecchio et al.
BIOCHEMICAL PHARMACOLOGY (2016)
BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly
Ulrike Garscha et al.
BIOCHEMICAL PHARMACOLOGY (2016)
Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors
Holger Kuhne et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
The risk of falling into poverty after developing heart disease: a survival analysis
Emily J. Callander et al.
BMC PUBLIC HEALTH (2016)
The Future of Arrhythmias and Electrophysiology
Christine M. Albert et al.
CIRCULATION (2016)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski et al.
EUROPEAN HEART JOURNAL (2016)
4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP)
Erden Banoglu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Synthesis, antiarrhythmic activity, and toxicological evaluation of mexiletine analogues
Mariagrazia Roselli et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Novel Dual Inhibitors of Secretory Phospholipase A(2) and Sphingomyelin Synthase: Design, Synthesis and Evaluation
Haojun Gong et al.
LETTERS IN DRUG DESIGN & DISCOVERY (2016)
Exploration of 6,7-dimethoxyquinazoline derivatives as dual acting alpha(1)-and AT(1)-receptor antagonists: synthesis, evaluation, pharmacophore & 3D-QSAR modeling and receptor docking studies
Neetesh Agrawal et al.
RSC ADVANCES (2016)
Physiological and Pathophysiological Insights of Nav1.4 and Nav1.5 Comparison
Gildas Loussouarn et al.
FRONTIERS IN PHARMACOLOGY (2016)
Platelet-Derived Growth Factor Signaling in the Lung From Lung Development and Disease to Clinical Studies
Nina Noskovicova et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2015)
Atherosclerosis
Hong Lu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Cardiac Arrhythmias: Diagnosis, Symptoms, and Treatments
Du-guan Fu
CELL BIOCHEMISTRY AND BIOPHYSICS (2015)
Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension
Benoit Ranchoux et al.
CIRCULATION (2015)
Contemporary Drug Development in Heart Failure Call for Hemodynamically Neutral Therapies
Muthiah Vaduganathan et al.
CIRCULATION-HEART FAILURE (2015)
Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications
Manuel de Lera Ruiz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Riociguat for the treatment of pulmonary hypertension
Nathan Hambly et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2015)
Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy
M. Volpe et al.
HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION (2015)
Selexipag for the treatment of pulmonary arterial hypertension
Nika Skoro-Sajer et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Design of Novel Potent Antihyperlipidemic Agents with Antioxidant/Anti-inflammatory Properties: Exploiting Phenothiazine's Strong Antioxidant Activity
Alexios N. Matralis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The Role of Sphingolipids in Arachidonic Acid Metabolism
Hiroyuki Nakamura et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2014)
2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Ezra A. Amsterdam et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Therapeutic approaches to drug targets in atherosclerosis
Prasad G. Jamkhande et al.
SAUDI PHARMACEUTICAL JOURNAL (2014)
Design and synthesis of 6,7-dimethoxyquinazoline analogs as multi-targeted ligands for α1- and AII-receptors antagonism
M. R. Yadav et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Combined Modifications of Mexiletine Pharmacophores for New Lead Blockers of Nav1.4 Channels
Michela De Bellis et al.
BIOPHYSICAL JOURNAL (2013)
Design, Synthesis, and Biological Evaluation of Novel Dual Inhibitors of Secretory Phospholipase A2 and Sphingomyelin Synthase
Xing Gao et al.
CHINESE JOURNAL OF CHEMISTRY (2013)
Design, synthesis, and biological evaluation of benzofuran derivatives as ET receptor antagonists
Jin Cai et al.
MEDICINAL CHEMISTRY RESEARCH (2013)
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Tomas Pulido et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy
Peter Libby
NEW ENGLAND JOURNAL OF MEDICINE (2013)
NESS002ie: A new fluorinated thiol endopeptidase inhibitor with antinociceptive activity in an animal model of persistent pain
Simone Tambaro et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2013)
Antihypertensive profile of 2-thienyl-3,4-methylenedioxybenzoylhydrazone is mediated by activation of the A2A adenosine receptor
Carla Moreira Leal et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2012)
Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy
Johanna Kuusisto et al.
HEART (2012)
Design and Synthesis of Dual Modulators of Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptors
Estella Buscato et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Targeting Peroxisome Proliferator-Activated Receptors (PPARs): Development of Modulators
Celine Pirat et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Design, Synthesis, and Pharmacological Evaluation of N-Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors
Arthur E. Kuemmerle et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist
Martin H. Bolli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Third Universal Definition of Myocardial Infarction
Kristian Thygesen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Endothelin receptor antagonists for the treatment of pulmonary artery hypertension
Lewis J. Rubin
LIFE SCIENCES (2012)
Spider-venom peptides that target voltage-gated sodium channels: Pharmacological tools and potential therapeutic leads
Julie K. Klint et al.
TOXICON (2012)
Novel Benzoxazine and Benzothiazine Derivatives as Multifunctional Antihyperlipidemic Agents
Alexios N. Matralis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Atherosclerosis: current pathogenesis and therapeutic options
Christian Weber et al.
NATURE MEDICINE (2011)
Mechanisms of disease: pulmonary arterial hypertension
Ralph T. Schermuly et al.
NATURE REVIEWS CARDIOLOGY (2011)
Cardiac arrhythmia and heart failure: From bench to bedside
Yong-Fu Xiao
JOURNAL OF GERIATRIC CARDIOLOGY (2011)
Design of more potent squalene synthase inhibitors with multiple activities
Angeliki P. Kourounakis et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Synthesis and In Vitro Sodium Channel Blocking Activity Evaluation of Novel Homochiral Mexiletine Analogs
Alessia Carocci et al.
CHIRALITY (2010)
Phosphinic Tripeptides as Dual Angiotensin-Converting Enzyme C-Domain and Endothelin-Converting Enzyme-1 Inhibitors
Nicolas Jullien et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Molecular hybridization, synthesis, and biological evaluation of novel chroman IKr and IKs dual blockers
Lupei Du et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors
Francesca Olimpieri et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Tadalafil Therapy for Pulmonary Arterial Hypertension
Nazzareno Galie et al.
CIRCULATION (2009)
Allosteric Modulators of the Adenosine A1 Receptor: Synthesis and Pharmacological Evaluation of 4-Substituted 2-Amino-3-benzoylthiophenes
Luigi Aurelio et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension
Ying-Ju Lai et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Targeting ACE and ECE with dual acting inhibitors
Stephen Hanessian et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Ambrisentan for the treatment of pulmonary arterial hypertension -: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
Nazzareno Galie et al.
CIRCULATION (2008)
Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches
Irina Savelieva et al.
EUROPACE (2008)
Tackling heart disease and poverty
Geraldine Lee et al.
NURSING & HEALTH SCIENCES (2007)
Structure/Function characterization of μ-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels
Min-Min Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The importance of endothelin-1 for vascular dysfunction in cardiovascular disease
Felix Boehm et al.
CARDIOVASCULAR RESEARCH (2007)
Dual acting antioxidant A1 adenosine receptor agonists
Alison Gregg et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
IKs block by HMR 1556 lowers ventricular defibrillation threshold and reverses the repolarization shortening by isoproterenol without rate-dependence in rabbits
Petsy Pui-Sze So et al.
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY (2007)
How to design multi-target drugs: target search options in cellular networks
Tamas Korcsmaros et al.
EXPERT OPINION ON DRUG DISCOVERY (2007)
Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-γ activation
Georg Hansmann et al.
CIRCULATION (2007)
Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: A potential risk factor for torsade de pointes
Sachin A. Shah et al.
PHARMACOTHERAPY (2007)
Blockade of I-Ks by HMR 1556 increases the reverse rate-dependence of refractoriness prolongation by dofetilide in isolated rabbit ventricles
Petsy Pui-Sze So et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators
Edward J. Mills et al.
PLOS MEDICINE (2006)
The benefits of the multi-target approach in drug design and discovery
LM Espinoza-Fonseca
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
Sildenafil citrate therapy for pulmonary arterial hypertension
N Galiè et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
An association between inflammatory state and left ventricular hypertrophy in hemodialysis patients
Y Erten et al.
RENAL FAILURE (2005)
Omapatrilat and enalapril in patients with hypertension: The omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial
OB Kostis et al.
AMERICAN JOURNAL OF HYPERTENSION (2004)
Cardiac hypertrophy: The good, the bad and the ugly
N Frey et al.
ANNUAL REVIEW OF PHYSIOLOGY (2003)
Function and solution structure of huwentoxin-IV, a potent neuronal tetrodotoxin (TTX)-sensitive sodium channel antagonist from Chinese bird spider Selenocosmia huwena
K Peng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Inhaled iloprost for severe pulmonary hypertension
H Olschewski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension - A double-blind, randomized, placebo-controlled trial
G Simonneau et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
RN Channick et al.
LANCET (2001)
Oxidative stress and cardiac disease
DJ Lefer et al.
AMERICAN JOURNAL OF MEDICINE (2000)
分享论文
